Celldex Therapeutics (CLDX) Accounts Payables (2010 - 2026)

Celldex Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $10.4 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 203.78% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (up 203.78% YoY), while the FY2025 annual figure was $1.2 million, down 63.86% from the prior year.
• Accounts Payables was $10.4 million for Q1 2026 at Celldex Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.4 million in Q1 2026 to a low of $881000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.3 million in 2024.
• Biggest YoY gain for Accounts Payables was 331.56% in 2024; the steepest drop was 68.93% in 2024.
• A 5-year view of Accounts Payables shows it stood at $3.3 million in 2022, then advanced by 4.61% to $3.5 million in 2023, then retreated by 6.55% to $3.3 million in 2024, then plunged by 63.86% to $1.2 million in 2025, then surged by 777.88% to $10.4 million in 2026.
• The last three Accounts Payables figures came in at $10.4 million (Q1 2026), $1.2 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.